{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:08:51Z","timestamp":1791526131254,"version":"4.3.4"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Junta de Andaluc\u00eda in Spain"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.coi.2018.03.006","type":"journal-article","created":{"date-parts":[[2018,3,19]],"date-time":"2018-03-19T14:20:58Z","timestamp":1521469258000},"page":"123-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"special_numbering":"C","title":["The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses"],"prefix":"10.1016","volume":"51","author":[{"given":"Natalia","family":"Aptsiauri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Ruiz-Cabello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2018.03.006_bib0385","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/322502a0","article-title":"MHC antigens and malignancy","volume":"322","author":"Festenstein","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.coi.2018.03.006_bib0390","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/bjc.1989.45","article-title":"HLA class I gene expression in human primary tumors and autologous metastasis: demonstration of selective losses of HLA antigens on colorectal, gastric and laryngeal carcinomas","volume":"59","author":"Lopez-Nevot","year":"1989","journal-title":"Br J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0395","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/0167-5699(93)90264-L","article-title":"Natural history of HLA expression during tumor development","volume":"14","author":"Garrido","year":"1993","journal-title":"Immunol Today"},{"key":"10.1016\/j.coi.2018.03.006_bib0400","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1749-6632.1993.tb43994.x","article-title":"Tumour escape from immune response by variation in HLA expression and other mechanisms","volume":"690","author":"Bodmer","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.coi.2018.03.006_bib0405","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0167-5699(96)10075-X","article-title":"Implications for immunosurveillance of altered HLA class I phenotypes in human tumors","volume":"18","author":"Garrido","year":"1997","journal-title":"Immunol Today"},{"key":"10.1016\/j.coi.2018.03.006_bib0410","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0065-2776(08)60911-6","article-title":"Escape of human solid tumors from T cell recognition: molecular mechanisms and functional significance","volume":"74","author":"Marincola","year":"2000","journal-title":"Adv Immunol"},{"key":"10.1016\/j.coi.2018.03.006_bib0415","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0065-230X(01)83005-0","article-title":"MHC antigens and tumor escape from immune surveillance","volume":"83","author":"Garrido","year":"2001","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.coi.2018.03.006_bib0420","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/scbi.2001.0404","article-title":"HLA class I antigen abnormalities and immune escape by malignant cells","volume":"12","author":"Seliger","year":"2002","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.coi.2018.03.006_bib0425","first-page":"1","article-title":"MHC antigen expression. I. Human tumors","volume":"vol 2-1","author":"Garrido","year":"1991"},{"key":"10.1016\/j.coi.2018.03.006_bib0430","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1084\/jem.191.6.961","article-title":"Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer","volume":"191","author":"Koopman","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2018.03.006_bib0435","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1046\/j.1365-2249.2000.01292.x","article-title":"CD8+ T cells are crucial for the ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3-methylcholantrene","volume":"121","author":"Boesen","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.coi.2018.03.006_bib0440","series-title":"Tumor Immunology and Immunotherapy","first-page":"1","article-title":"Adaptive T-cell immunity and tumor antigen recognition","author":"Romero","year":"2014"},{"key":"10.1016\/j.coi.2018.03.006_bib0445","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S","article-title":"Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1","volume":"80","author":"Marchand","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0450","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nm0398-328","article-title":"Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells","volume":"4","author":"Nestle","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/j.coi.2018.03.006_sbref0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.3008918","article-title":"Anti CTL-4 therapy broadens the melanoma-reactive CD8+ T cell response","volume":"6","author":"Kvistborg","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2018.03.006_bib0460","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1158\/1078-0432.CCR-13-2648","article-title":"CTLA4 blockade broadens the peripheral T cell receptor repertoire","volume":"20","author":"Robert","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2018.03.006_sbref0465","doi-asserted-by":"crossref","first-page":"e974759","DOI":"10.4161\/2162402X.2014.974959","article-title":"IFN-\u03b3 producing CD8+ cells modified to resist major immune checkpoints induce regression of MHC class I-deficient melanomas","volume":"4","author":"Buferne","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coi.2018.03.006_bib0470","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/ijc.29375","article-title":"Generation of MHC class I diversity in primary tumors and selection of the malignant phenotype","volume":"138","author":"Garrido","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0475","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00251-008-0303-5","article-title":"Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy","volume":"60","author":"Carretero","year":"2008","journal-title":"Immunogenetics"},{"key":"10.1016\/j.coi.2018.03.006_sbref0480","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/ijc.26471","article-title":"Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes","volume":"131","author":"Carretero","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_sbref0485","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/ijc.30489","article-title":"The absence of HLA class I expression in non-small cell lung cancer correlates with the tumor tissue structure and the pattern of T cell infiltration","volume":"140","author":"Perea","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0490","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3390\/vaccines5010007","article-title":"The escape of cancer from T cell mediated immune surveillance: HLA class I loss and tumor tissue architecture","volume":"5","author":"Garrido","year":"2017","journal-title":"Vaccines"},{"key":"10.1016\/j.coi.2018.03.006_bib0495","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s00251-004-0692-z","article-title":"Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21","volume":"56","author":"Maleno","year":"2004","journal-title":"Immunogenetics"},{"key":"10.1016\/j.coi.2018.03.006_bib0500","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00251-010-0494-4","article-title":"Frequent loss of heterozygosity in the \u03b22-microglobulin region of chromosome 15 in primary human tumors","volume":"63","author":"Maleno","year":"2011","journal-title":"Immunogenetics"},{"key":"10.1016\/j.coi.2018.03.006_bib0505","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00262-002-0296-0","article-title":"Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozigocity in chromosome region 6p21","volume":"51","author":"Maleno","year":"2002","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.coi.2018.03.006_bib0510","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00251-006-0111-8","article-title":"LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas","volume":"58","author":"Maleno","year":"2006","journal-title":"Immunogenetics"},{"key":"10.1016\/j.coi.2018.03.006_bib0515","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1034\/j.1399-0039.2000.550507.x","article-title":"Criteria to define HLA haplotype loss in human tumors","volume":"55","author":"Ramal","year":"2000","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.coi.2018.03.006_bib0520","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/(SICI)1097-0215(19990924)83:1<91::AID-IJC17>3.0.CO;2-4","article-title":"Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors","volume":"83","author":"Jimenez","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0525","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ijc.28338","article-title":"Immune escape of cancer cells with \u03b22-microglobulin loss over the course of metastatic melanoma","volume":"134","author":"del Campo","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0530","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/ijc.10906","article-title":"Complete loss of HLA class I antigen expression on melanoma cells: a result of successive mutational events","volume":"103","author":"Paschen","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0535","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0065-230X(08)60713-7","article-title":"HLA class I antigens in human tumors","volume":"67","author":"Garrido","year":"1995","journal-title":"Adv Cancer Res"},{"key":"10.1016\/j.coi.2018.03.006_bib0540","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00262-016-1947-x","article-title":"Rejection versus escape: the tumor MHC dilemma","volume":"66","author":"Garrido","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.coi.2018.03.006_bib0545","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combine genetic inactivation of \u03b22 microglobuline and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coi.2018.03.006_bib0550","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1034\/j.1399-0039.2003.00020.x","article-title":"Total loss of MHC class I antigens in colorectal tumors can be explained by two molecular pathways: \u03b22 microglobuline inactivation in MSI-positive tumors and LMP7\/TAP2 downregulation in MSI-negative tumors","volume":"61","author":"Cabrera","year":"2003","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.coi.2018.03.006_bib0555","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0198-8859(96)00145-0","article-title":"High frequency of altered HLA class I phenotypes in invasive breast carcinomas","volume":"50","author":"Cabrera","year":"1996","journal-title":"Hum Immunol"},{"key":"10.1016\/j.coi.2018.03.006_bib0560","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00262-015-1774-5","article-title":"Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance","volume":"65","author":"Carretero","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.coi.2018.03.006_bib0565","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/ijc.20499","article-title":"Coordinated downregulation of the antigen presentation machinery and HLA class I\/\u03b22-microglobuline complex is responsible for HLA-ABC loss in bladder cancer","volume":"113","author":"Romero","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0570","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00262-007-0411-3","article-title":"Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines","volume":"57","author":"M\u00e9ndez","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.coi.2018.03.006_bib0575","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s002510100371","article-title":"A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A *0301 allele in a prostate carcinoma cell line","volume":"53","author":"Jimenez","year":"2001","journal-title":"Immunogenetics"},{"key":"10.1016\/j.coi.2018.03.006_bib0580","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1399-0039.1996.tb02571.x","article-title":"Mechanisms of loss HLA-I expression in colorectal tumor cells","volume":"47","author":"Browning","year":"1996","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.coi.2018.03.006_bib0585","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1084\/jem.190.2.205","article-title":"Selective histocompatibility leucocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells","volume":"190","author":"Wang","year":"1999","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2018.03.006_bib0590","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1399-0039.1996.tb02574.x","article-title":"Characterization of a gastric tumor cell line defective in MHC class I inducibility by both alpha- and gamma-interferon","volume":"47","author":"Abril","year":"1996","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.coi.2018.03.006_sbref0595","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2018.03.006_sbref0600","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/ijc.25270","article-title":"\u2018Hard\u2019 and \u2018soft\u2019 lesions underlying the HLA Class I alterations in cancer cells: implications for immunotherapy","volume":"127","author":"Garrido","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0605","doi-asserted-by":"crossref","first-page":"6034","DOI":"10.1158\/1078-0432.CCR-14-0879","article-title":"MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro","volume":"20","author":"Angell","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2018.03.006_bib0610","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/path.4029","article-title":"The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells","volume":"227","author":"Romero","year":"2012","journal-title":"J. Pathol"},{"key":"10.1016\/j.coi.2018.03.006_sbref0615","doi-asserted-by":"crossref","first-page":"5999","DOI":"10.1073\/pnas.1602069113","article-title":"NLRC5\/MHC class I transactivator is a target for immune evasion in cancer","volume":"113","author":"Yoshihama","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2018.03.006_bib0620","first-page":"144","article-title":"Class I and II HLA antigen distribution in normal mucosa, adenoma and colon carcinoma: relation with malignancy and invasiveness","volume":"4","author":"Gutierrez","year":"1987","journal-title":"Exp Clin Immunogenet"},{"key":"10.1016\/j.coi.2018.03.006_bib0625","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/ijc.25733","article-title":"Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leucocyte antigen class I-deficient tumor cells","volume":"129","author":"Carretero","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0630","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/1097-0215(20010101)91:1<109::AID-IJC1017>3.0.CO;2-E","article-title":"Immunoselection by T lymphocytes generates repeated MHC class I-deficient metastatic tumor variants","volume":"91","author":"Garcia-Lora","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0635","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/ijc.11241","article-title":"MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components","volume":"106","author":"Garcia-Lora","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0640","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ijc.2910470716","article-title":"Heterogeneity of MHC-class-I antigens in clones of methylcholanthrene-induced tumors. Implications for local growth and metastasis","volume":"6","author":"Algarra","year":"1991","journal-title":"Int J Cancer Suppl"},{"key":"10.1016\/j.coi.2018.03.006_bib0645","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/ijc.28338","article-title":"Immune escape of cancer cells with \u03b22-microglobulin loss over the course of metastatic melanoma","volume":"134","author":"del Campo","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0650","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1158\/1078-0432.CCR-14-0567","article-title":"Genetic evolution of T-cell resistance in the course of melanoma progression","volume":"20","author":"Sucker","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2018.03.006_bib0655","first-page":"937","article-title":"Integration of high-risk human papillomavirus DNA is linked to the down-regulation of class I human leukocyte antigens by steroid hormones in cervical tumor cells","volume":"57","author":"Bartholomew","year":"1997","journal-title":"Cancer Res"},{"key":"10.1016\/j.coi.2018.03.006_bib0660","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00262-008-0587-1","article-title":"HER-2\/neu mediated down-regulation of MHC class I antigens processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice","volume":"58","author":"Vertuani","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.coi.2018.03.006_bib0665","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1399-0039.2009.01409.x","article-title":"Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue","volume":"75","author":"S\u00e1enz-L\u00f3pez","year":"2010","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.coi.2018.03.006_bib0670","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1186\/1479-5876-10-205","article-title":"Cancer classification using the Immunoscore: a worldwide task force","volume":"10","author":"Galon","year":"2012","journal-title":"J Transl Med"},{"key":"10.1016\/j.coi.2018.03.006_bib0675","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3389\/fimmu.2013.00089","article-title":"The schistosoma granuloma: friend or foe?","volume":"4","author":"Hams","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2018.03.006_bib0680","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nri3211","article-title":"Revisiting the role of granuloma in tuberculosis","volume":"12","author":"Ramakrishnan","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"Pt 1","key":"10.1016\/j.coi.2018.03.006_bib0685","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/1078-0432.498.11.2","article-title":"Control of T-cell-mediated immune response by HLA class I in human pancreatic carcinoma","volume":"11","author":"Ryschich","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2018.03.006_bib0690","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1349-7006.2007.00558.x","article-title":"HLA class I antigen expression is associated with a favourable prognosis in early stage non-small cell lung cancer","volume":"98","author":"Kikuchi","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.coi.2018.03.006_bib0695","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1056\/NEJM198704093161501","article-title":"A progress report on the treatment of 157 patients with advance cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2018.03.006_bib0700","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor infiltrating lymphocytes and an attenuated IL-2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2018.03.006_bib0705","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/14712598.2015.1036737","article-title":"Immuno-regulatory antibodies for the treatment of cancer","volume":"15","author":"Honeychurch","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.coi.2018.03.006_bib0710","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.it.2008.03.002","article-title":"The immunological constant of rejection","volume":"29","author":"Wang","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.coi.2018.03.006_bib0715","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00262-011-1027-1","article-title":"Immunotherapy eradicates metastases with reversible defects in MHC class I expression","volume":"60","author":"Garrido","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.coi.2018.03.006_bib0720","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00595","article-title":"Upregulation of HLA class I expression on tumor cells by the anti-EGFR antibody nimotuzumab","author":"Garrido","year":"2017","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.coi.2018.03.006_bib0725","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-3083.2009.02276.x","article-title":"Efficient recovery of HLA class I expression in human tumor cells after \u03b22-microglobulin gene transfer using adenoviral vector: implications for cancer immunotherapy","volume":"70","author":"del Campo","year":"2009","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.coi.2018.03.006_bib0730","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1399-0039.2011.01831.x","article-title":"Targeting tumor HLA class I expression to increase tumor immunogenicity","volume":"79","author":"del Campo Ana","year":"2012","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.coi.2018.03.006_bib0735","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/cgt.2014.32","article-title":"Adenovirus expressing \u03b22-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition","volume":"21","author":"del Campo","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.coi.2018.03.006_bib0740","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.coi.2018.03.006_bib0745","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2018.03.006_bib0750","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-016-0127-z","article-title":"Targetless T cells in cancer immunotherapy","volume":"3","author":"Thor Straten","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.coi.2018.03.006_bib0755","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00262-002-0332-0","article-title":"Analysis of HLA expression in human tumor tissues","volume":"52","author":"Cabrera","year":"2003","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.coi.2018.03.006_bib0760","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/path.1700440313","article-title":"The genetic and antigenic basis of tumor transplantation","volume":"44","author":"Gorer","year":"1937","journal-title":"J Pathol Bacteriol"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791517301176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791517301176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:36:49Z","timestamp":1760603809000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791517301176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":76,"alternative-id":["S0952791517301176"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2018.03.006","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2018.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}